Drug Profile
Opucolimab - Shanghai Henlius Biotech
Alternative Names: HLX-20; Recombinant Fully Human Anti-PD-L1 Monoclonal Antibody Injection - Shanghai Henlius BiotechLatest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Henlix Biotech
- Developer Henlix Biotech; Shanghai Henlius Biotech
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)
- 16 Nov 2021 Opucolimab is still in phase I trials in Solid tumours in Australia (Parenteral) (Shanghai Henlius Biotech pipeline, November 2021)
- 28 Sep 2021 No development reported - Preclinical for Solid tumours in Taiwan (Parenteral)